- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 01.08. | Lenz's Vizz wins FDA approval to crack 'large, untapped' market for presbyopia | ||
| 01.08. | Despite ongoing decline, Moderna's Spikevax sales beat expectations in Q2 | ||
| 01.08. | J&J coins the term '3rd opinion,' debuts awareness campaign to empower lung cancer patients | ||
| 01.08. | Merz Aesthetics gives sales and marketing leadership a face-lift | ||
| 01.08. | Alnylam exceeds $50B market cap as Amvuttra heart disease launch wows Wall Street | ||
| 31.07. | White House threatens to 'deploy every tool in our arsenal' to implement most-favored-nation drug pricing | ||
| 31.07. | Merck will lay off 6,000, reducing workforce by 8% in cost-cutting purge | ||
| 31.07. | Sanofi touts tariff resilience for rest of 2025 as CEO admits many unknowns persist | ||
| 31.07. | AstraZeneca's Alexion spotlights generalized myasthenia gravis for next entry in awareness-raising film series | ||
| 31.07. | HHS will demo drugmakers' 340B rebate model in limited pilot program | ||
| 31.07. | AbbVie's rumored $1B pursuit of Gilgamesh could fit into its growing neuroscience portfolio | ||
| 31.07. | Biogen raises sales outlook as Leqembi awaits FDA decision on new dosing option | ||
| 31.07. | Bristol Myers touts commercial execution, reckons with recent clinical setbacks | ||
| 31.07. | Evotec offloads France biosimilars plant to Sandoz for $300M | ||
| 31.07. | Moderna, working through operating cost and R&D cuts, to sideline 10% of global workforce by year-end | ||
| 31.07. | Vinay Prasad's exit signals FDA's probable slip toward more permissive regulation of cell and gene therapy: analyst | ||
| 31.07. | Lilly's Mounjaro shows its cardio benefits in Trulicity head-to-head trial | ||
| 30.07. | J&J, Legend crunch the multiple myeloma numbers in first Carvykti TV ad | ||
| 30.07. | Celltrion closes in on US plant purchase, dubbing drug substance facility 'fundamental' to tariff mitigation | ||
| 30.07. | FDA taps newly appointed George Tidmarsh as acting CBER leader after Prasad exit | ||
| 30.07. | Takeda wades through more Vyvanse declines, muses DTC model as US pricing uncertainty looms | ||
| 30.07. | Teva execs shrug off pharmaceutical tariff threat as turnaround strategy rolls forward | ||
| 30.07. | Despite Blenrep uncertainty, GSK sticks to its £40B sales projection for 2031 | ||
| 30.07. | Guardant taps James Van Der Beek to promote colon cancer screening blood test | ||
| 30.07. | Daré starts push to arouse interest in women's sexual health drug, tapping app for education drive |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .